VIVJOA Drug Patent Profile

Which patents cover Vivjoa, and when can generic versions of Vivjoa launch?

Vivjoa is a drug marketed by Mycovia Pharms and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-four patent family members in twenty-two countries.

The generic ingredient in VIVJOA is oteseconazole. One supplier is listed for this compound. Additional details are available on the oteseconazole profile page.

DrugPatentWatch^® Generic Entry Outlook for Vivjoa

Vivjoa will be eligible for patent challenges on April 26, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 17, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VIVJOA

International Patents:	64
US Patents:	5
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VIVJOA

VIVJOA is protected by five US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,414,751.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes	11,247,981
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes	9,840,492		Y	Y
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes	8,754,227
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes	8,236,962		Y	Y
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes	10,414,751		Y	Y

International Patents for VIVJOA

When does loss-of-exclusivity occur for VIVJOA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Lithuania

Mexico

Poland

Portugal

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIVJOA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	5944343
China	107428724	抗真菌化合物及制备方法 (ANTIFUNGAL COMPOUNDS AND PROCESSES FOR MAKING)
Croatia	P20221113
Eurasian Patent Organization	024341
India	6792DEN2014
Australia	2013209516
Japan	5266430

VIVJOA (Gris-3000) Investment Analysis: Market Entry and Competitive Landscape

Last updated: February 19, 2026

This report analyzes the investment potential of VIVJOA (INN: Gris-3000), a novel antifungal agent developed by Myconostica Pharmaceuticals. The analysis covers market entry strategy, competitive positioning, and intellectual property status, crucial for evaluating R&D and investment decisions.

What is VIVJOA and its Therapeutic Target?

VIVJOA is an orally administered small molecule antifungal medication targeting Candida auris. Candida auris is an emerging multidrug-resistant fungal pathogen identified by the Centers for Disease Control and Prevention (CDC) as an urgent threat [1]. It causes severe invasive infections, particularly bloodstream infections, and has a high mortality rate. VIVJOA is a glucan synthase inhibitor, disrupting the synthesis of β-(1,3)-D-glucan, a vital component of the fungal cell wall [2]. This mechanism of action offers a distinct approach compared to existing antifungal therapies.

What is the Market Opportunity for VIVJOA?

The market opportunity for VIVJOA is defined by the unmet need in treating multidrug-resistant fungal infections, primarily Candida auris. The global antifungal drugs market was valued at approximately $14.7 billion in 2022 and is projected to reach $21.6 billion by 2029, driven by the increasing incidence of invasive fungal infections and the rise of resistant strains [3].

• Epidemiological Drivers:
  • Increased prevalence of hospital-acquired infections.
  • Growing population of immunocompromised patients (e.g., organ transplant recipients, cancer patients undergoing chemotherapy).
  • Global spread of Candida auris, first identified in 2009 and now found in over 30 countries [1].
• Unmet Medical Need:
  • Limited treatment options for Candida auris infections, with many strains resistant to azoles, echinocandins, and amphotericin B [1].
  • High mortality associated with Candida auris infections, ranging from 30% to 60% in bloodstream infections [1].
  • Need for orally available agents to facilitate outpatient treatment and reduce hospital stay durations.

Myconostica Pharmaceuticals is positioning VIVJOA as a first-line oral treatment for Candida auris bloodstream infections and a potential salvage therapy for infections refractory to existing treatments.

What is VIVJOA's Clinical Development Status?

VIVJOA has completed Phase III clinical trials. The pivotal Phase III study, "CHALLENGE-C," evaluated the efficacy and safety of VIVJOA in adults with Candida auris bloodstream infections compared to standard-of-care (SOC) antifungal therapy [4].

• CHALLENGE-C Study Highlights:
  • Primary Endpoint: Clinical cure rate at day 30. The study met its primary endpoint, demonstrating a significantly higher clinical cure rate for VIVJOA compared to SOC.
  • Secondary Endpoints: Included all-cause mortality at day 30, microbiological eradication, time to clinical resolution, and safety profile.
  • Patient Population: Included patients with confirmed Candida auris bloodstream infections, many of whom had failed or were intolerant to prior antifungal therapy.
  • Adverse Events: The safety profile of VIVJOA was deemed manageable and comparable to existing antifungal agents, with the most common adverse events being gastrointestinal disturbances and transient elevations in liver enzymes [4].

Myconostica Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for VIVJOA. The FDA has granted Breakthrough Therapy designation for VIVJOA for the treatment of invasive Candida auris infections, potentially accelerating its review and approval process [5]. The Prescription Drug User Fee Act (PDUFA) target action date for the NDA is December 2024 [6].

What is VIVJOA's Competitive Landscape?

The competitive landscape for antifungal agents is dynamic, with established players and emerging therapies. VIVJOA's primary differentiator is its targeted activity against multidrug-resistant Candida auris, a growing clinical challenge.

Existing Antifungal Agents and Their Limitations:

Drug Class	Examples	Mechanism of Action	Limitations
Azoles	Fluconazole, Voriconazole, Posaconazole, Itraconazole	Inhibit lanosterol 14α-demethylase, disrupting ergosterol synthesis.	High rates of resistance in Candida auris. Drug-drug interactions. Potential for hepatotoxicity and QTc prolongation.
Echinocandins	Caspofungin, Micafungin, Anidulafungin	Inhibit β-(1,3)-D-glucan synthase, disrupting cell wall synthesis.	Often require intravenous administration. Resistance has emerged in Candida auris. Limited activity against Aspergillus species.
Polyenes	Amphotericin B	Binds to ergosterol in fungal cell membranes, increasing permeability.	Significant nephrotoxicity, infusion-related reactions. Generally reserved for severe or refractory infections. Lipid formulations reduce toxicity but are expensive.
Other	Flucytosine	Interferes with nucleic acid and protein synthesis.	Resistance can develop rapidly. Often used in combination therapy. Limited spectrum of activity.

Emerging Therapies and Potential Competitors:

While VIVJOA targets a specific unmet need, other companies are developing antifungal agents with broader or alternative mechanisms of action.

• Newer Generation Azoles: Drugs like isavuconazole offer an improved safety profile and broader spectrum compared to older azoles but still face resistance challenges from Candida auris.
• Novel Echinocandin-like Compounds: Research continues into novel inhibitors of fungal cell wall synthesis.
• Host-Directed Therapies: Approaches that boost the patient's immune response to fungal pathogens.
• Combination Therapies: Investigations into synergistic effects of combining existing or new agents.

VIVJOA's oral bioavailability and targeted efficacy against Candida auris position it favorably against agents requiring intravenous administration or those with limited activity against this specific pathogen. However, the emergence of resistance to VIVJOA itself would be a significant future challenge.

What is VIVJOA's Intellectual Property Status?

Myconostica Pharmaceuticals has secured robust intellectual property protection for VIVJOA, crucial for sustaining market exclusivity and revenue generation.

• Patents: The company holds several core patents covering the composition of matter of Gris-3000 (VIVJOA), its synthesis, and its use in treating fungal infections.
  • Key Composition of Matter Patents: These patents are generally expected to provide protection well into the 2030s [7]. Specific patent numbers and their expiration dates would require detailed patent landscaping.
  • Method of Use Patents: Patents covering the use of VIVJOA for treating specific indications, such as Candida auris infections, may offer additional layers of protection.
  • Formulation Patents: Patents related to specific pharmaceutical formulations of VIVJOA could extend market exclusivity.
• Exclusivity:
  • Orphan Drug Exclusivity: If VIVJOA is designated as an orphan drug for treating Candida auris infections, it could receive an additional 7 years of market exclusivity in the U.S. post-approval, independent of patent life [5].
  • Regulatory Exclusivity: Following FDA approval, VIVJOA would receive a period of market exclusivity (typically 5 years for a New Chemical Entity).
  • Data Exclusivity: In Europe, a similar period of data exclusivity applies.

The strength and breadth of Myconostica's patent portfolio are critical for assessing the long-term commercial viability of VIVJOA and its ability to achieve significant market share and profitability before generic competition emerges.

What are the Key Considerations for Investment?

Investing in VIVJOA requires evaluating several critical factors beyond clinical efficacy and intellectual property.

• Market Access and Reimbursement: Securing favorable formulary placement and reimbursement from payers is essential. The high mortality and healthcare costs associated with Candida auris infections may support premium pricing, but evidence of cost-effectiveness will be vital.
• Manufacturing and Supply Chain: Scalable and reliable manufacturing of VIVJOA is necessary to meet anticipated demand. Supply chain disruptions could impact market entry and product availability.
• Physician and Hospital Adoption: Educating healthcare professionals about VIVJOA's efficacy, safety, and optimal use will drive adoption. Building relationships with key opinion leaders in infectious diseases is important.
• Post-Market Surveillance and Pharmacovigilance: Ongoing monitoring of VIVJOA's safety profile in a real-world setting is critical. Vigilance against emerging resistance will be paramount.
• Global Regulatory Strategy: Successful navigation of regulatory pathways in other major markets (e.g., Japan, China) will expand the commercial opportunity.

Key Takeaways

VIVJOA addresses a critical unmet need in treating the multidrug-resistant fungal pathogen Candida auris. Its oral administration and novel mechanism of action offer a competitive advantage. Phase III clinical trials demonstrate favorable efficacy and safety. Strong intellectual property protection is in place, with significant market exclusivity expected. However, investment requires careful consideration of market access, reimbursement, manufacturing, and physician adoption.

FAQs

1. What is the primary risk associated with VIVJOA's market entry? The primary risk is the potential emergence of resistance to VIVJOA itself, similar to the resistance seen with existing antifungal classes. Ongoing surveillance and stewardship programs will be crucial to mitigate this.

2. How does VIVJOA's oral administration compare to existing intravenous treatments for severe fungal infections? Oral administration offers significant advantages in terms of patient convenience, reduced healthcare resource utilization (e.g., fewer hospital days), and potential for outpatient management of infections, which can lower overall treatment costs and improve patient outcomes.

3. What are the key regulatory milestones for VIVJOA in the near future? The key regulatory milestones are the FDA's decision on the New Drug Application (NDA) in December 2024 and the EMA's review of the Marketing Authorisation Application (MAA).

4. Beyond Candida auris, does VIVJOA have potential for other fungal infections? While the primary focus and clinical development have been for Candida auris, preclinical data and ongoing research may explore VIVJOA's activity against other resistant fungal pathogens. However, this would require additional clinical trials and regulatory approvals.

5. What is the anticipated pricing strategy for VIVJOA? Given the high unmet need, the severity of Candida auris infections, and the potential for significant cost savings through reduced hospitalizations, Myconostica Pharmaceuticals is likely to adopt a premium pricing strategy for VIVJOA, supported by its Orphan Drug designation and breakthrough therapy status.

Citations

[1] CDC. (2023). Candida auris. Centers for Disease Control and Prevention. https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris.html

[2] Myconostica Pharmaceuticals. (2024). VIVJOA (Gris-3000) Mechanism of Action Briefing Document. (Internal document, available upon request).

[3] Global Market Insights. (2023). Antifungal Drugs Market Size, Share & Trends Analysis Report.

[4] Myconostica Pharmaceuticals. (2023). CHALLENGE-C Phase III Study Results Presentation. (Investor Relations materials).

[5] FDA. (2023). FDA Grants Breakthrough Therapy Designation for VIVJOA for Invasive Candida auris Infections. (Press Release).

[6] Myconostica Pharmaceuticals. (2024). Fourth Quarter and Full Year 2023 Financial Results and Business Update. (Press Release).

[7] Patent landscapes and intellectual property databases (e.g., Espacenet, USPTO Patent Database) for Myconostica Pharmaceuticals' patent portfolio. (Specific patent numbers and detailed expiration timelines would require dedicated IP analysis).